rhodium has been researched along with Triple Negative Breast Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gibson, H; Herroon, MK; Kodanko, JJ; Podgorski, I; Thummel, RP; Toupin, N; Turro, C | 1 |
| Ko, CN; Leung, CH; Ma, DL; Vellaisamy, K; Wong, SY; Yang, GJ; Ye, M; Zhong, HJ | 1 |
| Law, BYK; Leung, CH; Ma, DL; Miao, XM; Mok, SWF; Wang, W; Wong, CY; Wong, VKW; Wu, C; Wu, KJ; Yang, GJ; Zhong, HJ | 1 |
3 other study(ies) available for rhodium and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Metalloimmunotherapy with Rhodium and Ruthenium Complexes: Targeting Tumor-Associated Macrophages.
Topics: Cell Line, Tumor; Humans; Immunotherapy; Rhodium; Ruthenium; Triple Negative Breast Neoplasms; Tumor-Associated Macrophages | 2022 |
Identification of a rhodium(iii) complex as a Wee1 inhibitor against TP53-mutated triple-negative breast cancer cells.
Topics: Cell Cycle Proteins; Cell Line; Coordination Complexes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Mutation; Nuclear Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Rhodium; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2018 |
Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Coordination Complexes; Female; Histones; Humans; Iridium; Mice; Mice, Inbred BALB C; Retinoblastoma-Binding Protein 2; Rhodium; Transplantation, Heterologous; Triple Negative Breast Neoplasms | 2018 |